Search the Newsreel

Marcus & Millichap Q2 Earnings Call Highlights

Key Points Interested in Marcus & Millichap, Inc.? Here are five stocks we like better. Strong Q2 recovery: Revenue rose 18% to $203 million, while net income improved to $4 million from an $11 million loss a year earlier. Adjusted EBITDA increased to $12 …

Marcus & Millichap (NYSE:MMI) Stock Rating Upgraded by Wall Street Zen

Marcus & Millichap (MMI) Stock Rallies Back To Profit As Valuation Questions Linger

Arcus Biosciences (RCUS) Stock Gets Fair Value Bump After Casdatifan Optimism

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. The fair value estimate for Arcus Biosciences has shifted from US$35.75 to US$38.00, signaling …

Marcus & Millichap publishes investor presentation on CRE investment sales, financing brokerage strategy and 2025 performance

Marcus & Millichap's investor presentation outlined a strategic plan focusing on recruitment, proprietary technology, targeted acquisitions, and expanding financing operations. The company projects 2025 revenues of $755 million, a total transaction volume of $51 billion, and 8,818 transactions. Despite a net loss of $2 …

Circus SE: Umsatzprognose auf 5,2 Mio. Euro gekappt – Aktie bricht ein

Arcus Biosciences (NYSE: RCUS) gets 24.7% ownership from Gilead

Gilead Sciences, Inc. has reported a beneficial ownership of 24.7% in Arcus Biosciences, Inc. (NYSE: RCUS), holding 31,424,760 shares out of 127,333,376 outstanding. This stake was built through multiple equity purchases dating back to 2020 and is linked to an Option, License and Collaboration …

Marcus & Millichap Brokers $9.5 Million Sale of Single-Tenant Retail Property in Walterboro, South Carolina

Marcus & Millichap has facilitated the sale of a newly constructed gas station and convenience store in Walterboro, South Carolina, for $9.5 million. The 4,824-square-foot property is occupied by 7-Eleven and a CAT Scale weigh station. Haris Hanifi and Robert Filley of Marcus & …

Marcus Corp (MCS) Stock News Today

This article provides an overview of Marcus Corp (MCS) stock, including its current trading price, market capitalization, and P/E ratio. It notes that the news section for MCS will feature the latest stock news, earnings, analyst ratings, and key developments, with more updates expected …

Marcus & Millichap Brokers Sale of 984-Unit Self-Storage Facility in Phoenix

Marcus & Millichap has successfully brokered the sale of a 984-unit Extra Space Storage facility in Phoenix, Arizona. The facility, built in 2021, offers fully climate-controlled units and a range of security features. The LeClaire-Schlosser Group of Marcus & Millichap represented the seller in …

Marcus & Millichap (NYSE: MMI) lifts Q2 revenue and expands buybacks

Marcus & Millichap reported a strong Q2 2026 financial performance, with total revenue increasing to $202.9 million, up 17.8% from the previous year, driven by higher real estate brokerage commissions and financing fees. The company also turned a net loss of $11.0 million in …

Marcus & Millichap, Inc. Q2 2026: Revenue $202.9M, EPS $0.1— 10-Q Summary

Marcus & Millichap, Inc. (MMI) reported strong second-quarter 2026 results with revenue of $202.9 million, an increase of 17.8% year-over-year, and a net income of $3.9 million, reversing a loss from the prior-year quarter. Diluted EPS stood at $0.10. The company's growth was fueled …

Private Investors Drive Surge in NNN-Leased Restaurant Deals

This story was originally published on CRE Daily. Join 70,000+ commercial real estate professionals getting daily news, market insights, and industry analysis delivered straight to their inbox with the free CRE Daily newsletter. Key Takeaways Transaction volume for single-tenant, triple-net retail rose 18% through …

Press Release: Marcus & Millichap, Inc. Reports Preliminary Results for Second Quarter 2026

Marcus & Millichap, Inc. has released its preliminary results for the second quarter of 2026. This announcement provides an early look into the company's financial performance for the recent quarter. The full details will likely be disclosed in an upcoming official earnings report.

Arcus Biosciences (RCUS) Stock Can Casdatifan Carry Mounting Losses

Arcus Biosciences (RCUS) reported Q2 2026 revenue of US$41m against a net loss of US$91m, indicating a substantial decline from the previous year. While the stock initially saw a pop, concerns persist regarding the company's high burn rate, reliance on partners, and concentrated pipeline …

Marcus & Millichap Brokers $5.3M Sale of Multifamily Property in Miami Beach Florida

Marcus & Millichap has announced the sale of an 24-unit multifamily property in Miami Beach, Florida, for $5.3 million. The property was purchased by a New York-based private investment group, indicating continued strong demand from nonlocal investors for South Florida real estate. The asset, …

Arcus Biosciences Inc (RCUS) News, Articles, Events & Latest Updates

Arcus Biosciences (RCUS) recently reported its Q2 2026 financial results, exceeding revenue estimates despite a reported loss. The company is actively advancing its pipeline, including new clinical collaborations for casdatifan and ivonescimab in cancer treatments. An analyst from HC Wainwright also increased Arcus Biosciences' …

Earnings Flash (RCUS) Arcus Biosciences, Inc. Reports Q2 Revenue $41.0M

Arcus Biosciences, Inc. (RCUS) reported Q2 revenue of $41.0 million. Wedbush adjusted its price target on Arcus Biosciences to $43 from $41, maintaining an Outperform rating. The company is a clinical-stage biopharmaceutical company focused on developing differentiated molecules and combination therapies for cancer, with …

Arcus Biosciences (NYSE:RCUS) Price Target Raised to $26.00

Wells Fargo & Company has raised its price target for Arcus Biosciences (NYSE:RCUS) from $23.00 to $26.00, while maintaining an "equal weight" rating. This new target implies a potential downside of 5.75% from the stock's previous close. Despite this, the company has a "Moderate …

Marcus & Millichap (MMI) Q2 Results Put Its Valuation Back In Focus

Marcus & Millichap (MMI) reported its Q2 2026 results, showing a return to profitability and continued capital returns through buybacks and dividends, which garnered fresh attention. While the company's stock has seen recent positive momentum, Simply Wall St's analysis suggests it is 11.6% overvalued …

Marcus & Millichap Q2 2026 slides: profitability returns amid CRE recovery

Marcus & Millichap reported a significant return to profitability in Q2 2026, beating analyst expectations with revenue of $202.9 million, up 17.8% year-over-year. The company saw net income turn positive to $3.9 million from an $11.0 million loss, and Adjusted EBITDA surged 732.6% to …

Arcus Biosciences, Inc. Stock 12‑Month Price Target Raised to $38.25, Implies 38% Upside

The average 12-month price target for Arcus Biosciences, Inc. stock has increased from $37.17 to $38.25, based on estimates from 12 analysts. This new target suggests a potential upside of approximately 38% from the August 5 closing price. The consensus rating among 13 analysts …

Marcus & Millichap, Inc. 2026 Q2 - Results - Earnings Call Presentation (NYSE:MMI) 2026-08-06

Marcus & Millichap, Inc. (MMI) released its Q2 2026 earnings call presentation. The slide deck provides detailed results discussed during the call. The article was prepared by SA Transcripts, which focuses on publishing quarterly earnings call transcripts.

Circus SE: Prognosekürzung, Kurscrash und operativer Start in der Ukraine

Marcus & Millichap Brokers Sale of Six-Property Self-Storage Portfolio in Oregon

Marcus & Millichap has successfully brokered the sale of a six-property self-storage portfolio in Oregon, comprising 3,545 units across 537,962 square feet. The portfolio, known as Secure Storage, includes facilities in Ashland, Bend, Prineville, Redmond, Hood River, and Hillsboro, with two properties offering land …

Earnings Flash (MMI) Marcus & Millichap, Inc. Reports Q2 Revenue $202.9M, vs. FactSet Est of $194.3M

Marcus & Millichap, Inc. (MMI) reported stronger-than-expected Q2 revenue of $202.9 million, surpassing FactSet's estimate of $194.3 million. This positive earnings flash indicates a robust financial performance for the real estate services company during the second quarter of 2026. The company also announced a …

Marcus & Millichap (NYSE:MMI) Surprises With Strong Q2 CY2026

Marcus & Millichap (NYSE:MMI) reported stronger-than-expected revenue and GAAP profit for Q2 CY2026, with sales up 17.8% year-on-year to $202.9 million and EPS of $0.10, significantly beating analyst estimates. Despite a historical decline in long-term revenue and EPS growth, the company showed improved operating …

Marcus & Millichap Posts $3.9M Q2 Profit After Year-Earlier Loss

Marcus & Millichap (MMI) reported a Q2 2026 net income of $3.9 million, or $0.10 per diluted share, a significant turnaround from a net loss of $11.0 million in Q2 2025. This improvement was driven by a 17.8% increase in total revenue to $202.9 …

Marcus & Millichap (NYSE: MMI) posts Q2 2026 revenue of $202.9M

Marcus & Millichap reported a return to profitability in Q2 2026, with total revenue increasing by 17.8% to $202.9 million and net income reaching $3.9 million, or $0.10 per diluted share, compared to a net loss in the prior year. The company also declared …

Form 4 Marcus Corp For: 6 August By Investing.com

This article from Investing.com is a regulatory filing notification, specifically a Form 4 for Marcus Corp, dated August 6. It indicates an insider transaction or change in beneficial ownership for the company. The content itself is very brief and mostly surrounded by website navigation …

Lazard Asset Management LLC Acquires Shares of 49,140 Marcus Corporation (The) $MCS

Lazard Asset Management LLC has acquired 49,140 shares of The Marcus Corporation (NYSE:MCS) during the first quarter, a new position valued at approximately $844,000, representing a 0.16% stake. Other institutional investors have also adjusted their holdings in Marcus, with a total of 81.57% of …

Arcus Biosciences (NYSE:RCUS) Releases Earnings Results, Beats Expectations By $0.17 EPS

Marcus Corp (NYSE: MCS) exec exercises 110,500 options, withholds shares

Marcus Corp executive Thomas F. Kissinger exercised stock options for 110,500 shares on August 3, 2026, with strike prices ranging from $21.84 to $28.88. To cover the exercise price and tax obligations, 89,451 shares were delivered or withheld. Kissinger retains options for additional shares …

Arcus Biosciences, Inc. 2026 Q2 - Results - Earnings Call Presentation (NYSE:RCUS) 2026-08-05

Arcus Biosciences, Inc. (NYSE:RCUS) published its Q2 2026 earnings call presentation, reporting an EPS of -$0.72, which beat estimates by $0.09. The company's revenue for the quarter was $41.00M, exceeding expectations by $19.02M, despite a 74.38% year-over-year decrease. This presentation was released in conjunction …

Arcus Biosciences (NYSE: RCUS) posts Q2 loss, ends Gilead options

Arcus Biosciences reported a Q2 2026 net loss of $91 million, or $0.72 per share, with total revenues of $41 million, a significant decrease from $160 million in Q2 2025 due to the absence of a large one-time payment from Gilead. Broad Gilead option …

Arcus Adds Three Kidney Cancer Trials as 2026 Data Near

Arcus Biosciences reported its second-quarter 2026 financial results, with revenues of $41 million and a net loss of $91 million. The company is strategically advancing its HIF-2α inhibitor, casdatifan, for clear cell renal cell carcinoma (ccRCC) through three new clinical trial collaborations and anticipates …